# Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia

> **NCT06942507** · NA · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 104 (estimated)

## Conditions studied

- Waldenström's Macroglobulinemia (WM)

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Bendamustine + Rituximab

## Key facts

- **NCT ID:** NCT06942507
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06942507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06942507, "Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06942507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*